Continuing the fight against HIV
Three decades later, we continue to work to find new ways to treat and prevent HIV through ViiV Healthcare. This partnership between GSK and Pfizer combines the HIV expertise of both companies and Shionogi, who joined in 2012 following a long-term collaboration on the joint development of several novel integrase inhibitors.
In 2015, we struck an innovative public-private partnership with the University of North Carolina at Chapel Hill and Qura Therapeutics. Together, we have established the Cure Center, which focuses on the latest scientific approaches to fighting HIV. This includes investigational work on “shock and kill”, which makes any hidden HIV visible to the immune system and attempts to enhance the patient’s immune system to clear out the virus.
And more than thirty years on, Marty continues to work to find new ways to treat and prevent HIV infection, in her role as clinical director for ViiV Healthcare. She is optimistic about the strides that have been made in HIV treatment – and the outlook for innovation in HIV.
“We’ve pretty much given people their lives back,” said Marty. “It’s a hopeful time.”
 Morb Mortal Wkly Rep.1984;33(24):337
 Morb Mortal Wkly Rep.1984;33(47):661
 UNAIDS fact sheet http://www.unaids.org/en/resources/fact-sheet (accessed March 2017)